Arthneeti
Latest: Strides Pharma Science Ltd Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
SP

Strides Pharma Science Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Strides Pharma Science Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹1,045
Market cap₹9.6K Cr
P/E16.6
Updated16 Oct 2026
Read5 min read

What the Q1 FY27 call signalled

0 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexNo capex planned

The short version

Strides aims to grow its U.S. Strides Pharma Science expects steady revenue growth driven by diversified businesses, particularly strong momentum in Ex-US markets. - Operational EBIT margin was maintained around 18.2% despite geopolitical and cost pressures. - Operational PAT grew 8% year-on-year with steady EBITDA-to-PAT conversion of 54%. - Reported PAT increased 56.7% due to a gain from divesting Pivot Path. - The company aims to maintain gross margins within 58-60% range. - Return on Capital Employed (ROCE) is expected to improve as recent investments mature. - Management focused on profitability and portfolio quality rather than growth at any cost for U.S.

From Strides Pharma Science Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Moderate growth
  • Strides aims to grow its U.S. business from USD 285 million to USD 375 million by FY28, driven by five levers including OTC business, controlled substances, new product launches, specialty channels, and new partnerships.
  • Controlled substances are expected to contribute significantly to growth following completion of past sales history demonstration (1.5 years demonstrated), with higher quota allocations anticipated from next cycles.
  • Approximately 10 product launches are planned by March next year, focusing on higher-revenue potential products (USD 10-15 million each).
  • Beyond FY28, growth is expected to be driven by advancements in three key domains—nasal sprays, transdermal patches, and thin films—with multiple filings and launches planned over next 12-18 months.

2 more points from Strides Pharma Science Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Strides Pharma Science Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

No capex planned
  • Current capex is a combination of maintenance capex, R&D, and hard capex, totaling about INR 2.5 to 3 billion per year.
  • No greenfield capex is planned at this point; focus remains on enhancing existing factories and investing in high-impact line items.
  • Strategic investment includes the sale of majority stake in Pivot Path, with retained 20% interest, expected to contribute to PAT in the next 4-5 years.
  • The company continues investments in new technology platforms like nasal sprays, transdermal patches, films, and controlled substances to support future growth.

2 more points from Strides Pharma Science Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Strides Pharma Science Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights from the call include: - The company highlighted delays in product approvals impacting near-term launches but expects growth in the U.S. from new approvals and launches in H2 FY27. - Controlled substances quota allocations, occurring bi-annually, have taken longer but are expected to improve in upcoming cycles, driving growth. - There is mention of supply chain logistics causing some temporary fulfillment issues in ex-U.S. markets, which the company aims to recover in subsequent quarters.

2 more points from Strides Pharma Science Ltd's call on order book

Create a free account to keep reading this call

Strides Pharma Science Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.4K Cr, net profit ₹134 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Strides Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Strides Pharma Science Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Strides Pharma Science Ltd Q1 FY27 results?

Strides aims to grow its U.S. Strides Pharma Science expects steady revenue growth driven by diversified businesses, particularly strong momentum in Ex-US markets. - Operational EBIT margin was maintained around 18.2% despite geopolitical and cost pressures. - Operational PAT grew 8% year-on-year with steady EBITDA-to-PAT conversion of 54%. - Reported PAT increased 56.7% due to a gain from divesting Pivot Path. - The company aims to maintain gross margins within 58-60% range. - Return on Capital Employed (ROCE) is expected to improve as recent investments mature. - Management focused on profitability and portfolio quality rather than growth at any cost for U.S.

What is Strides Pharma Science Ltd share price analysis?

Strides Pharma Science Ltd currently shows a below-average growth signal. The stock trades at a P/E of 16.6 with a market cap of ₹9,633 Cr. Investors should review the full earnings analysis for detailed insights.

Is Strides Pharma Science Ltd planning capital expenditure?

Current capex is a combination of maintenance capex, R&D, and hard capex, totaling about INR 2.5 to 3 billion per year.

Keep Strides Pharma Science Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.